A FormBlends network publication

Survodutide: the glucagon and GLP-1 dual agonist (investigational)

Boehringer Ingelheim's once-weekly GLP-1 plus glucagon receptor agonist: phase 2 dose-finding, the 2026 phase 3 obesity result of minus 13.0% at 76 weeks, the MASH program, and what the placebo arm in that trial tells you. Not FDA approved.

By FormBlends editorial teamUpdated September 4, 2026Educational, not medical advice

Survodutide is the glucagon idea without the GIP idea. Where retatrutide activates three receptors, survodutide activates GLP-1 and glucagon receptors only, which makes it the cleanest test of what glucagon agonism adds to a GLP-1 drug. Its developers pursued liver disease alongside obesity from the start, because glucagon receptor activation in the liver is expected to reduce fat there.

Mechanism and receptor profile

A once-weekly subcutaneous peptide with dual agonist activity at the glucagon receptor and the GLP-1 receptor, described that way in the phase 2 title. No label, so no FDA-reviewed mechanism statement.

Regulatory status

No application in Drugs@FDA as of 4 September 2026. The phase 3 obesity trial was published in the New England Journal of Medicine in 2026; the SYNCHRONIZE program includes trials in obesity, obesity with type 2 diabetes, obesity with MASLD, and a trial in Chinese adults.

Trials and their numbers

Headline results from the abstracts
TrialPopulation and durationResultPubMed
Phase 3, obesity725 adults with obesity or overweight plus a weight-related condition, mean BMI 37.9; 76 weeksWeight -12.2% (3.6 mg), -13.0% (6.0 mg) vs -5.4% placebo; 72.6%, 71.9% and 46.3% lost 5% or more; gastrointestinal adverse events 80.9%, 89.7% and 47.9%; no deaths42253238
Phase 2, obesity387 adults with obesity or overweight, no diabetes; 46 weeksWeight -6.2% (0.6 mg), -12.5% (2.4 mg), -13.2% (3.6 mg), -14.9% (4.8 mg) vs -2.8% placebo; 60.4% completed the treatment period; adverse events in 91% vs 75%, gastrointestinal in 75% vs 42%38330987
Phase 2, MASH with fibrosisAdults with biopsy-confirmed MASH and fibrosisPublished in N Engl J Med 2024; histology endpoints reported in the paper38847460

Two features of the phase 3 abstract deserve a slow read. The placebo arm lost 5.4%, roughly double the placebo loss in STEP 1 or SURMOUNT-1, so the placebo-adjusted effect is about 7.6 percentage points at 6.0 mg. And the 6.0 mg arm added only 0.8 points over 3.6 mg while gastrointestinal events rose from 80.9% to 89.7%. Those are the trade-offs a label would eventually have to describe.

Adverse events

No label table. From the abstracts: gastrointestinal events dominate and were described as typically mild to moderate in phase 3; in phase 2 only 60% of participants completed 46 weeks, which is a discontinuation rate well above the approved agents' trials.

Boxed warning

None; no label exists.

Manufacturer

Boehringer Ingelheim funded the trials.

Where next

The other GLP-1 plus glucagon agent, mazdutide, has phase 3 results in Chinese adults. The approved, investigational and compounded guide explains what "phase 3 published" does and does not mean for availability.

Questions people ask

Why was the placebo weight loss so large in the phase 3 trial?

The abstract reports minus 5.4% on placebo at 76 weeks, against 2% to 3% in most placebo arms of this class. The placebo-adjusted difference (about 7.6 points at 6.0 mg) is therefore smaller than the raw number suggests. The full paper, not the abstract, explains the lifestyle program and population that produced it.

Is survodutide being developed for liver disease?

Yes. A phase 2 trial in MASH with fibrosis was published in 2024, and a phase 3 trial in obesity with MASLD (SYNCHRONIZE-MASLD) was published in 2026. Neither is an approval.

Canonical URL: https://formblendsglp1s.com/agents/survodutide. Written by the FormBlends editorial team. This page is educational and is not medical advice; see the medical disclaimer.